Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2000-06-15
2002-09-24
Geist, Gary (Department: 1623)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S027130
Reexamination Certificate
active
06455690
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to the field of nucleosides.
BACKGROUND OF THE INVENTION
Mammalian immune systems contain two major classes of lymphocytes: B lymphocytes (B cells), which originate in the bone marrow; and T lymphocytes (T cells) which originate in the thymus. B cells are largely responsible for humoral immunity (i.e., antibody production), while T cells are largely responsible for cell-mediated immunity.
T cells are generally considered to fall into two subclasses, helper T cells and cytotoxic T cells. Helper T cells activate other lymphocytes, including B cells and cytotoxic T cells, and macrophages, by releasing soluble protein mediators called cytokines which are involved in cell-mediated immunity. As used herein, lymphokines are a subset of cytokines.
Helper T cells are also generally considered to fall into two subclasses, Th1 and Th2. Th1 cells (also known as Type 1 cells) produce interleukin 2 (IL-2), tumor necrosis factor (TNF&agr;) and interferon gamma (IFN&ggr;), and are responsible primarily for cell-mediated immunity such as delayed type hypersensitivity and antiviral immunity. In contrast, Th2 cells (also known as Type 2 cells) produce interleukins, IL4, IL-5, IL-6, IL-9, IL-10 and IL-13, and are primarily involved in assisting humoral immune responses such as those seen in response to allergens, e.g. IgE and 1gG4 antibody isotype switching (Mosmann, 1989,
Annu Rev Immunol,
7:145-173).
As used herein, the terms Th1 and Th2 “responses” are meant to include the entire range of effects resulting from induction of Th1 and Th2 lymphocytes, respectively. Among other things, such responses include variation in production of the corresponding cytokines through transcription, translation, secretion and possibly other mechanisms, increased proliferation of the corresponding lymphocytes, and other effects associated with increased production of cytokines, including motility effects.
The mechanisms by which nucleosides and other compounds selectively modulate Th1 and Th2 responses relative to each other are still unclear. One possibility contemplated by the present inventors is that effective nucleosides alter the pool of guanosine triphosphate (GTP), which in turn affects the rate at which cytokines are produced. In this theory, relatively large variations in available GTP are sufficient to affect concentrations of both Th1 and Th2 cytokines, while relatively smaller variations in available GTP tend to affect concentrations of Th1 and Th2 cytokines to different extents.
These discoveries are especially significant because modern treatment strategies for many of the above-listed diseases have either limited effectiveness, significant side effects, or both. Treatment of autoimmune disease, for example, is frequently limited to palliative measures, removal of toxic antibodies (as in myasthenia gravis), and administration of hazardous drugs including corticosteroids, chloroquine derivatives, and antimetabolic or antitumor drugs, and drugs such as cyclosporines which target immune system cells.
SUMMARY OF THE INVENTION
This application relates to novel nucleosides. Nucleosides contemplated are those nucleosides corresponding to Formulas 1 and 2.
REFERENCES:
patent: 4746651 (1988-05-01), Goodman
patent: WO98/16184 (1998-04-01), None
patent: WO98/30223 (1998-07-01), None
Nagahara et al., “Thiazolo[4,5-d]pyrimidine Nucleosides. The Synthesis of Certain 3-&bgr;-D-Ribofuranosylthiazolo[4,5-d]pyrimidines as Potential Immunotherapeutic Agents,”Journal of Medicinal Chemistry,33(1), 407-415 (Jan., 1990).*
Smee et al., “Broad Spectrum In Vivo Antiviral Activity of 7-Thia-8-Oxoguanosine, a Novel Immunopotentiating Agent,”Antimicrobial Agents and Chemotherapy,33(9), 1487-1492 (Sep., 1989).
Averett Devron
Ramasamy Kanda
Tam Robert
Wang Guangyi
Crane L. E.
Fish Robert D.
Fish & Associates, LLP
Geist Gary
LandOfFree
L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2846199